BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33785321)

  • 1. Texture features of primary tumor on
    Aydos U; Ünal ER; Özçelik M; Akdemir D; Ekinci Ö; Taştepe AI; Memiş L; Atay LÖ; Akdemir ÜÖ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Mar; ():. PubMed ID: 33785321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Texture features of primary tumor on
    Aydos U; Ünal ER; Özçelik M; Akdemir D; Ekinci Ö; Taştepe Aİ; Memiş L; Atay LÖ; Akdemir ÜÖ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(6):343-350. PubMed ID: 34752367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value on SUV-derived parameters assessed on
    Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R
    BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [
    Wang D; Zhang X; Liu H; Qiu B; Liu S; Zheng C; Fu J; Mo Y; Chen N; Zhou R; Chu C; Liu F; Guo J; Zhou Y; Zhou Y; Fan W; Liu H
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4692-4704. PubMed ID: 35819498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Histogram-Based Textural Analysis of
    Önner H; Coşkun N; Erol M; Eren Karanis Mİ
    Mol Imaging Radionucl Ther; 2022 Feb; 31(1):33-41. PubMed ID: 35114750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary tumor heterogeneity on pretreatment
    Gülbahar Ateş S; Bilir Dilek G; Uçmak G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(4):223-230. PubMed ID: 36690032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Laws Be a Potential PET Image Texture Analysis Approach for Evaluation of Tumor Heterogeneity and Histopathological Characteristics in NSCLC?
    Karacavus S; Yılmaz B; Tasdemir A; Kayaaltı Ö; Kaya E; İçer S; Ayyıldız O
    J Digit Imaging; 2018 Apr; 31(2):210-223. PubMed ID: 28685320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of diffusion kurtosis imaging and
    Feng P; Shao Z; Dong B; Fang T; Huang Z; Li Z; Fu F; Wu Y; Wei W; Yuan J; Yang Y; Wang Z; Wang M
    Front Oncol; 2022; 12():989131. PubMed ID: 36248958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
    Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
    Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Texture Analysis on [
    Bianconi F; Palumbo I; Fravolini ML; Chiari R; Minestrini M; Brunese L; Palumbo B
    Mol Imaging Biol; 2019 Dec; 21(6):1200-1209. PubMed ID: 30847822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
    BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Histopathological Features of Early-stage Invasive Ductal Breast Carcinoma by
    Erol M; Önner H; Eren Karanis Mİ
    Mol Imaging Radionucl Ther; 2021 Oct; 30(3):129-136. PubMed ID: 34658227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.
    Kim DH; Song BI; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2051-7. PubMed ID: 24990401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The exploration of quantitative intra-tumoral metabolic heterogeneity in dual-time
    Jia G; Zhang J; Li R; Yan J; Zuo C
    Abdom Radiol (NY); 2021 Sep; 46(9):4218-4225. PubMed ID: 33866381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study.
    Kanzaki R; Higashiyama M; Fujiwara A; Tokunaga T; Maeda J; Okami J; Kozuka T; Hosoki T; Hasegawa Y; Takami M; Tomita Y; Kodama K
    Lung Cancer; 2011 Mar; 71(3):333-7. PubMed ID: 20619479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.